" class="no-js "lang="en-US"> FondaMental Fondation - Medtech Alert
Sunday, September 07, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
FondaMental Foundation | Pharmtech Focus

FondaMental Fondation

About FondaMental Fondation

FondaMental Fondation

The FondaMental Foundation is a scientific cooperation foundation dedicated to the fight against major psychiatric disorders. It combines cutting-edge care and research to promote personalized and multidisciplinary management of severe psychiatric disorders. To speed up mental illnesses and promote personalized medicine in psychiatry, the FondaMental Foundation has set itself four missions: – to improve early diagnosis, treatment, and prognosis; – to accelerate research in psychiatry; – to disseminate knowledge; – to break down prejudices.

Related Story

COVID-19

 Syndrome Post-COVID: First Results of the Collaboration Between Fondamental & GeNeuro | Pharmtech Focus

Syndrome Post-COVID: First Results of the Collaboration Between Fondamental & GeNeuro

April 13 2022

GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune […]